Transneuronix
Transneuronix operates as a medical device company in the United States and Europe
About Transneuronix
Transneuronix, Inc. operated as a medical device company with a specific focus on developing therapies for obesity. Founded in 1995 and based in Mount Arlington, New Jersey, the firm dedicated its research to the application of gastric electrical stimulation. The core of its business was the development of an implantable, pacemaker-like device intended to treat obesity by sending electrical pulses to the stomach. This device, known as the Transcend Implantable Gastric Stimulation (IGS) System, was designed to create a feeling of fullness, thereby reducing appetite and helping patients lose weight. The system included an implantable stimulator, a programming system, a software application card, and gastric stimulation leads.
The company's primary clients were obese individuals participating in clinical research studies. Transneuronix's business model revolved around the research, development, and eventual commercialization of this medical device. The company engaged in extensive clinical trials across the U.S. and Europe to validate the safety and efficacy of its gastric stimulation technology. A significant milestone for Transneuronix was the development of its Transcend system, which underwent multi-center studies to confirm its effectiveness in weight loss with minimal complications compared to control groups. The first gastric stimulator for treating morbid obesity based on this research was implanted in 1995.
On July 1, 2005, Transneuronix was acquired by Medtronic for approximately $260 million, a move that marked Medtronic's entry into the obesity treatment sector and led to the formation of its Medtronic Obesity Management business unit. The acquisition was considered a strategic failure for Medtronic in subsequent years. Following the acquisition, Medtronic continued the development of the technology, creating the Transcend II IPG. However, no gastric electrical stimulation (GES) devices have received FDA approval for the treatment of obesity in the United States, although the Transcend IGS was available in Europe for this purpose.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1995
- Headquarters
- Mount Arlington, United States
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Weight Management, Surgery, Metabolism, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2005 | $269M | $269M | Medtronic | — |
| SERIES B✓Equity / VC | Dec 2004 | $17M | $67M | Affinity Capital Management · Affinity Capital Management | — |
Growth signals
Latest recorded traffic for Transneuronix is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Affinity Capital Management
Other known investors1 additional known investor
Medtronic
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Transneuronix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Transneuronix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







